Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Doxazosin
Drug ID BADD_D00718
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]
Marketing Status approved
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D07874
MeSH ID D017292
PubChem ID 3157
TTD Drug ID D03MIR
NDC Product Code 16729-213; 43063-739; 50268-224; 58657-820; 58657-821; 63629-7891; 0049-2040; 0049-2614; 70518-3667; 71335-0309; 71610-043; 42291-258; 50090-0734; 51655-476; 55154-7996; 58657-823; 0049-2080; 68084-836; 68084-851; 68788-8422; 70771-1114; 71205-690; 59762-2420; 60505-0094; 66267-377; 68071-3298; 68382-784; 68788-8412; 58657-822; 68382-783; 70518-2183; 16729-211; 42291-259; 42291-260; 0049-2410; 70934-728; 71335-0002; 23155-095; 50090-2153; 50090-5773; 60505-0093; 68084-862; 68382-786; 68788-7328; 0904-5523; 0904-5524; 23155-093; 50090-0701; 50090-0706; 50268-225; 60505-0095; 70518-1560; 70518-1804; 70771-1112; 70934-921; 16729-414; 23155-094; 50090-3927; 50090-5540; 59762-2440; 60505-0096; 0049-2716; 68382-785; 68788-7149; 70771-1113; 70771-1115; 23155-092; 51655-109; 59762-2480; 71610-153; 72189-117; 16729-415; 50090-0704; 50268-223; 0049-2512; 71335-0349; 71610-160; 71610-628; 0904-5522; 50268-222; 59762-2410
UNII NW1291F1W8
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C23H25N5O5
CAS Registry Number 74191-85-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.0010.000113%
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000395%
Acute myocardial infarction02.02.02.001; 24.04.04.0010.000282%Not Available
Aggression19.05.01.0010.000113%Not Available
Agitation19.06.02.001; 17.02.05.012--
Alopecia23.02.02.001--
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000338%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000113%Not Available
Aneurysm24.02.01.001--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.0090.000508%Not Available
Anxiety19.06.02.0020.000530%
Apathy19.04.04.002--Not Available
Arrhythmia02.03.02.0010.000169%Not Available
Arthralgia15.01.02.0010.000564%
Arthritis15.01.01.001--
Asthenia08.01.01.0010.001117%Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.0020.000395%
Atrioventricular block02.03.01.0020.000113%Not Available
Back pain15.03.04.005--
Benign prostatic hyperplasia21.04.02.0010.000113%Not Available
Bladder pain20.02.02.001--Not Available
Blood pressure normal13.14.03.010--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000508%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 11 Pages